Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ATYR with free AI briefings, catalyst countdowns, and dilution alerts.

ATYR · aTyr Pharma, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$48.8M Cash on Hand
15.5mo Cash Runway
Follow ATYR by email Get an email when ATYR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ATYR, unsubscribe in one click. Privacy

📣 What ATYR Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Efzofitimod Pulmonary Sarcoidosis Phase 3 · NCT05415137 Completed
ATYR1940 Facioscapulohumeral Muscular Dystrophy Phase 1/2 · NCT02836418 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ATYR holds $48.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $9.4M/quarter from operations, an estimated runway of 15.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 43 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ATYR files for a raise →

👥 Who Owns ATYR

Insiders 67.1% Institutions (98 holders) 25.9% Public and other holders 7%
HolderTypeShares% of sharesAs of
Paul Schimmel
Director · +124,000 options
Insider 1,421,913 55.78% 2026-05-27
Sanjay Shukla
President and CEO, Director · +2.50M options
Insider 153,553 6.02% 2026-02-03
Timothy Coughlin
Director · +100,000 options
Insider 56,000 2.20% 2024-05-30
Jill Marie Broadfoot
Chief Financial Officer · +687,500 options
Insider 37,296 1.46% 2026-02-03
Nancy Denyes
General Counsel · +687,500 options
Insider 33,124 1.30% 2026-02-03
Jane A Gross
Director · +124,000 options
Insider 9,750 0.38% 2025-03-17

Share count 2,549,230 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ATYR picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ATYR and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.